Product name: Ceftazidime for injection
Shelf Life: 3 Years
Ceftazidime for injection
This product is the main ingredient of ceftazidime, plus appropriate amount of sodium carbonate as a cosolvent.
Chemical Name: (6R, 7R)-7-[[(2-amino-4-thiazolyl)-[(1-carboxy-1-methylethoxy)imino]acetyl]amino]-2-carboxyl 8-Oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-methylpyridinium salt pentahydrate.
Molecular Formula: C22H22N6O7S2·5H2O
Molecular weight: 636.65
This product is white or almost white crystalline powder.
This product can be used for sensitive gram-negative bacillus-induced sepsis, lower respiratory infections, celiac biliary infections, complicated urinary tract infections and severe skin and soft tissue infections. It is particularly suitable for infections caused by immunodeficiency caused by multiple resistant gram-negative bacilli, nosocomial infections, and central nervous system infections caused by Gram-negative bacilli or Pseudomonas aeruginosa.
Before use, add sterile water for injection to dissolve.
Sepsis, lower respiratory infections, biliary infections and other daily 4-6 grams, 2 to 3 times intravenous or intravenous injection, treatment 10 to 14 days.
Urinary tract infections and severe skin and soft tissue infections such as daily 2 to 4 grams, divided into 2 intravenous or intravenous injections, treatment 7 to 14 days.
For certain life-threatening infections, severe Pseudomonas aeruginosa infections and central nervous system infections, 150-200 mg/kg per day may be taken incrementally, divided into 3 infusions or intravenously.
Infants and young children commonly used daily dose of 30 ~ 100mg/kg, 2 to 3 times intravenous infusion, the maximum daily dose does not exceed 6 grams.
The adverse reactions of this product are rare and slight with an incidence of about 2.5%. Rare skin rash (0.5% to 2%), pruritus, drug fever; nausea, diarrhea, abdominal pain; mild phlebitis at the injection site; occasional transient serum transaminases (SGPT), blood urea nitrogen, and serum creatinine levels Mildly elevated; leukocytes, thrombocytopenia, and eosinophilia. Lighter or moderately reversible glomerular filtration rate reductions have also been reported during the course of treatment. Coombs test positive patients occurred in 5% of patients, hemolytic anemia and thrombocytosis occasionally, reversible neutropenia seen in individual patients. The incidence of double infection is 2.5%. Common pathogens include Enterococcus and Candida.
It is forbidden to have a history of allergic reactions to this product or to cephalosporin antibiotics. Patients with a history of penicillin anaphylactic shock should avoid using this product.
1. Before using this product, it is necessary to ask in detail about whether the patient has previously had a history of allergies to this product, other cephalosporins, penicillins, or other drugs. This product is used with caution in patients with penicillin allergies, due to cross-sensitization may occur. When anaphylactic shock is applied to this product, emergency measures such as epinephrine, maintaining airway patency, oxygen absorption, glucocorticoids, and antihistamines are required.
2. Those with a history of gastrointestinal disease, especially ulcerative colitis, localized colitis, or antibiotic-associated colitis should be used with caution (cephalosporins rarely produce pseudomembranous colitis).
3. When patients with renal insufficiency use conventional doses, the drug concentration may increase and the half-life may be prolonged. Therefore, patients with renal insufficiency need to be reduced in application. Elevated plasma concentrations can cause convulsions, encephalopathy, flapping wing tremor, neuromuscular excitement, and myoclonus.
Sealed and kept in a cool place (not darker than 20°C).